More effective depression treatments exist—so why aren’t they used? Everbright on TMS, esketamine, and the barriers to prescribing | Ben Kuhn
This episode features Ben Kuhn, CEO of Everbright Health, discussing treatments for depression such as TMS and esketamine. He addresses the obstacles to their widespread adoption in independent practices, including complex payer criteria and operational burdens. The conversation…